– New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding – XIENCE is the most used drug eluting stent in the world, and European […]
Tag: DAPT
Medtronic Announces One-Month DAPT Clinical Study in the U.S. and Japan with Resolute Onyx DES in High Bleeding Risk Patients
(GLOBE NEWSWIRE via COMTEX) —The Onyx ONE Clear Study Builds Upon Body of Clinical Evidence to Inform Individualized DAPT Duration Following Stent Procedures DUBLIN – September 10, 2018 – Medtronic plc (NYSE:MDT) today announced the start of the Onyx ONE Clear […]
Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology
DUBLIN- August 14, 2017 – Medtronic plc (NYSE: MDT) today announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) – the combination of aspirin and an anti-clotting medication – in patients implanted with the Resolute Onyx(TM) […]
First patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patients
PCRonline/News/Industry Press Releases – 04 April, 2017 MASTER-DAPT kicks-off with the enrolment of its first patient by Treant Zorggroep, Scheper Hospital Emmen, The Netherlands – Dr Gillian Jessurun from Treant Zorggroep, Scheper Hospital has enrolled the first patient in the investigator […]